Valuation: BioNTech SE

Market Cap 20.8B 23.75B 19.16B 17.79B 33.77B 2,266B 34.23B 229B 89.26B 1,112B 89.2B 87.25B 3,856B P/E 2026 *
-18.7x
P/E 2027 * -18.4x
Enterprise Value 9.95B 11.36B 9.17B 8.51B 16.16B 1,084B 16.37B 110B 42.7B 532B 42.67B 41.73B 1,845B EV / Sales 2026 *
4.59x
EV / Sales 2027 * 5.17x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-0.58%
Current month-8.24%
Current year-8.24%
3 years 81.2
Extreme 81.2
115.95
5 years 81.2
Extreme 81.2
396.5
10 years 11.5
Extreme 11.5
396.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 60 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 55 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.58%-0.24% - - 23.75B
-0.32%-0.10%+73.99%+132.80% 57.73B
-0.93%-2.54%+73.64%+93.71% 54.69B
-0.05%+6.49%+14.05%+451.36% 24.18B
-2.86%+6.13%+46.59%-2.86% 19.82B
+2.50%+4.43%+43.31%-27.09% 17.14B
+3.58%+13.78%+196.41%+348.55% 16.75B
-2.67%+17.03%+44.86% - 15.57B
-0.57%+2.30%+20.33%+187.27% 13.96B
+0.26%+0.42%+77.16%+140.09% 12.21B
Average -0.14%+5.89%+65.59%+165.48% 25.78B
Weighted average by Cap. -0.31%+4.42%+66.88%+154.05%

Financials

2026 *2027 *
Net sales 2.17B 2.47B 1.99B 1.85B 3.52B 236B 3.56B 23.88B 9.29B 116B 9.29B 9.08B 401B 2.23B 2.55B 2.05B 1.91B 3.62B 243B 3.67B 24.59B 9.57B 119B 9.56B 9.35B 413B
Net income -1.05B -1.2B -968M -898M -1.71B -114B -1.73B -11.59B -4.51B -56.18B -4.51B -4.41B -195B -1.17B -1.33B -1.07B -996M -1.89B -127B -1.92B -12.85B -5B -62.3B -5B -4.89B -216B
Net Debt -10.85B -12.39B -10B -9.28B -17.62B -1,182B -17.86B -120B -46.57B -580B -46.53B -45.51B -2,012B -9.28B -10.6B -8.55B -7.93B -15.07B -1,011B -15.27B -102B -39.82B -496B -39.8B -38.92B -1,720B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-07-07 81.45 -0.85% 346
26-07-06 €82.15 -2.26% 11,250
26-07-03 €84.05 -1.23% 6,674
26-07-02 €85.10 +3.21% 5,537
26-07-01 €82.45 +1.23% 1,883
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
82.26EUR
Average target price
106.82EUR
Spread / Average Target
+29.85%

Quarterly revenue - Rate of surprise